Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - tibolone 2,5 mg - tablet - tibolone

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

strides pharma uk ltd - tibolone - oral tablet - 2.5mg

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdowell pharmaceuticals - tibolone - tablets - 2.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

profind wholesale ltd. - tibolone - tablets - 2.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - tibolone - tablets - 2.5 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - tibolone -

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - tibolone -

New Zealand - English - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - tibolone 2.5mg;   - tablet - 2.5 mg - active: tibolone 2.5mg   excipient: ascorbyl palmitate lactose monohydrate magnesium stearate potato starch - · treatment of symptoms resulting from the natural or surgical menopause in post-menopausal women. women above 60 years of age should only start with livial treatment when they are intolerant of or contraindicated for other medicinal products approved for the treatment of oestrogen deficiency symptoms. · prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - tibolone - tablets - tibolone 2.5 mg - tibolone - tibolone - • complaints resulting from the natural or artificial menopause.treatment of oestrogen deficiency symptoms in postmenopausal women, more than one year after menopause. women above 60 years of age should only start with livial treatment when they are intolerant of, or contraindicated for, other medicinal products approved for the treatment of oestrogen deficiency symptoms.• prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.for all women the decision to prescribe tibolone livial should be based on an assessment of the individual patient’s overall risks and, particularly in the over 60s, should include consideration of the risk of stroke.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdowell pharmaceuticals - tibolone - tablets - 2.5 milligram